Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Clever Culture Systems Limited (CC5.AX)
Adelaide, SA, AU
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.70% | -12.50% | +0.00% | -22.22% | -27.59% | -27.59% | +10.53% | -18.92% | -66.67% | -80.00% | -85.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Software - Infrastructure: +13.7%+334.8% ★
-
EPS growth Software - Infrastructure: +28.7%+120.0% ★
-
FCF margin FCF growth · Software - Infrastructure: +32.2%+30.8% Q2'25: +31.8%
-
EBIT margin Software - Infrastructure: +8.8%-0.1% Q2'25: -25.9%
-
ROIC Software - Infrastructure: +6.6%-0.1% Q2'25: -24.9%
-
Share dilution Software - Infrastructure: +0.0%+124.3%
-
Debt / EBITDA Net debt/EBITDA · Software - Infrastructure: -1.06×10.07× Q2'25: -0.90×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2024 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
1.26M
est: 29.60M (-95.8%)
|
1.80M
1.80M – 1.80M
-93.9% YoY
|
4.00M
4.00M – 4.00M
+122.2% YoY
|
7.70M
7.70M – 7.70M
+92.5% YoY
|
| EBITDA |
-4.05M
est: -21.90M (+81.5%)
|
-1.33M
-1.33M – -1.33M
+93.9% YoY
|
-2.96M
-2.96M – -2.96M
-122.2% YoY
|
-5.70M
-5.70M – -5.70M
-92.5% YoY
|
| EBIT |
-4.29M
est: -22.21M (+80.7%)
|
-1.35M
-1.35M – -1.35M
+93.9% YoY
|
-3.00M
-3.00M – -3.00M
-122.2% YoY
|
-5.78M
-5.78M – -5.78M
-92.5% YoY
|
| Net Income |
-3.74M
est: 64.83M (-105.8%)
|
-631.5K
-631.5K – -631.5K
-101.0% YoY
|
4.21M
4.21M – 4.21M
+766.7% YoY
|
7.37M
7.37M – 7.37M
+75.0% YoY
|
| SGA |
4.36M
est: 66.32M (-93.4%)
|
4.03M
4.03M – 4.03M
-93.9% YoY
|
8.96M
8.96M – 8.96M
+122.2% YoY
|
17.25M
17.25M – 17.25M
+92.5% YoY
|
| EPS |
0.00
est: 0.03 (-113.0%)
|
0.00
0.00 – 0.00
-101.0% YoY
|
0.00
0.00 – 0.00
+766.7% YoY
|
0.00
0.00 – 0.00
+75.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-01 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brenton John Barnes | CEO, MD & Director | 346.0K | male |
| Raymond Robert Ridge | CFO & Company Secretary | 132.0K | male |
| Jack Brown | Corporate Development Director | — | male |
| Steven Giglio | Scientific Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CC5.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
